Poster zum Thema "Multiomics Approaches"

Zurück
  • iP-20
Expanding proteomics horizons through metadata
  • Tine Claeys (Ghent / BE)
  • P-II-0505
Exploring sex differences in zebrafish livers using a novel targeted discovery metabolomics approach
  • P-II-0506
TurboOmics: a web-based platform for the analysis of transcriptomics, proteomics and untargeted metabolomics data using a multi-Omics integrative approach
  • P-II-0507
Integrative multi-omic analysis reveals conserved cell-projection deficits in human down syndrome brains
  • P-II-0508
Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets
  • P-II-0509
Development of a multi-omics sample preparation workflow for comprehensive metabolomics, lipidomics and proteomics datasets using a single tissue sample
  • P-II-0510
Single-Cell proteomics and transcriptomics: unveiling cellular complexity
  • P-II-0511
Delineation of signaling routes that underlie differences in macrophage phenotypic states
  • P-II-0513
Ligand-receptor cellular networks from bulk and single-cell proteomics data
  • P-II-0514
Multi-proteomics unveils multi-level dysregulations in methylmalonic acidemia
  • P-II-0515
Multi-omics approach for unraveling novel Gaucher disease biomarkers on dried blood spot
  • P-II-0516
Direct probing of the energy-information axis in embryonic stem cells and cancer using a multi-omics histone-metabolome-proteome workflow
  • P-II-0517
Exploring cisplatin resistance in cancer using mass spectrometry-based bioanalytical tools and patient-derived xenograft cell models
  • P-II-0518
Urine biomarkers for diagnosis of pancreatic cancer
  • P-II-0519
Proteo-Metabo-Flux – linking Acetyl-CoA and acetylation dynamics for accurate determination of histone acetylation rates
  • P-II-0521
Assessment of data-independent acquisition mass spectrometry for the identification of single amino acid variants
  • P-II-0522
Exploring the ghost proteome in ovarian cancer cells by proteogenomic characterization and cross-linking mass spectrometry
  • P-II-0523
Computational analysis of proteome and secretome of human pluripotent stem cells
  • P-II-0524
Multi-omics analysis of host responses in tracheal tissues of pigs after infection with a human- and swine-adapted influenza A viruses
  • P-II-0525
Groningen proteogenomics workflow for detecting a wide range protein variants in LC-MS/MS data
  • P-II-0526
The comprehensive SARS-CoV-2 "hijackome" knowledge base
  • P-II-0527
Ubiquitinomic profiling of CYLD cutaneous syndrome skin tumours identifies an insulin signalling axis
  • P-II-0528
Factor analysis based methods for an integrated unsupervised analysis of multi-omics data
  • P-II-0529
Inference of mechanistic insights from multi-omics data facilitating the drug discovery process
  • P-II-0530
A comprehensive multi-OMICS integration framework to address sample heterogeneity and identify causative genes and proteins in the pathogenesis of Keratoconus
  • P-II-0531
Human embryonic stem cells (hESC) epitranscriptome forms epitranslatome and translation profiles
  • P-II-0532
Proteomic profiling of paired primary tumors and brain metastases from lung adenocarcinoma patients uncovers phenotypic changes during disease progression
  • P-II-0533
Alternative splicing derived proteoforms show tissue-specific expression and rewire intrinsically disordered regions
  • P-II-0534
Comprehensive Solution of Ultrasensitive Proteome Technology (CS-UPT) combined with low-input multi-omics analysis provides new insights and clues for mouse maternal-to-zygotic transition
  • P-II-0535
Integral-Omics: serial profiling of metabolome, lipidome, genome, transcriptome, whole proteome, and phosphoproteome in biopsy tissue
  • P-II-0536
Time-resolved metabolite and lipid profiling depicts macrophage continuum with apoptotic and ferroptotic heterogeneity along foam cell formation
  • P-II-0537
Metaproteomic profiling of pediatric patients microbiota with acute lymphoblastic leukemia: impact of chemotherapy
  • P-II-0538
Multi-omics characterization of the monkeypox virus infection
  • P-II-0539
Uncovering new proteins in Alzheimer's disease patients by quantitative proteomics: blood-based markers and their connection to Amyloid-beta plaques
  • P-II-0540
Proteogenomic profiling to identify therapeutic targets for acute myeloid leukaemia
  • P-II-0541
Multi-omics characterization of childhood Rhabdomyosarcoma
  • P-II-0542
Relation between cardiovascular health and Alzheimer: unraveling the role of lipid metabolism and related proteins through DIA-PASEF
  • P-II-0543
APOC2 protein as a cornerstone in the development of Aortic stenosis, in patients with Type 2 diabetes mellitus
  • P-II-0544
Unraveling the protein phosphorylation and glycosylation landscape of diffuse large B-Cell lymphoma using multilayer proteomics and integrative multiomics
  • P-II-0545
Precision through Networks: AI-driven Targeting of Protein-Protein Interactions in Lysosomal Storage Disorders
  • P-II-0547
NCI's clinical proteomic tumor analysis consortium: analysis tools and resources
  • P-II-0548
Using established biorepositories for emerging research questions: a feasibility study
  • P-II-0549
Characterisation of redox post-translational modifications upon acute antioxidant treatment in the diabetic heart, using quantitative mass spectrometry
  • P-II-0551
Exploring serine metabolism in Alzheimer's disease and astrocyte differentiation
  • P-II-0553
Multi-proteomics in bleeding and hemostasis
  • P-II-0554
The development of SDRF-Metaproteomics metadata standards: harmonizing efforts from proteomics and metagenomics
  • P-II-0555
Multi-omics profiling of bone regeneration in diabetes reveals association of increased mast cell activity with healing impairment
  • P-II-0556
Microfluidics coupled with mass spectrometry-based multi-omics for antimicrobial resistance analysis
  • P-II-0557
Multi-omics analysis reveals mechanosensitive alterations in cardiac Metabolome during pathological remodeling
  • P-II-0558
Spatially resolved proteogenomics on human melanoma samples reveals evolutionary trajectories in tumor progression
    • v1.20.0
    • © Conventus Congressmanagement & Marketing GmbH